核酸逆转录酶抑制剂暴露与较低的阿尔茨海默病风险有关:一项回顾性队列概念验证研究
Tiffany W Chow1,2, Mark Raupp1, Matthew W Reynolds1
1IQVIA, Durham, NC 27703, USA.
Pharmaceuticals (Basel, Switzerland)
|April 27, 2024
概括
用于艾滋病毒的核酸逆转录酶抑制剂 (NRTIs) 可能降低阿尔茨海默病 (AD) 风险. 这项研究发现,与未暴露或对照组相比,暴露于NRTI的HIV患者的AD发病率较低.
科学领域:
- 神经科学是一个神经科学.
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
背景情况:
- 体基因重组 (SGR) 和内源逆转录酶 (RTs) 与阿尔茨海默病 (AD) 病因相关.
- 这表明RT抑制剂可能是阿尔茨海默病的潜在预防或治疗药物.
研究的目的:
- 以核酸RT抑制剂 (NRTIs) 的暴露为基础,评估患有人类免疫缺陷病毒 (HIV) 个体的AD发病率.
- 调查NRTI作为预防或治疗阿尔茨海默病的预防或治疗策略的潜力.
主要方法:
- 追溯性,概念验证研究,使用非识别的美国医疗索赔数据.
- 分析了三个队列:暴露于NRTI的HIV患者 (队列1),未暴露于NRTI的HIV患者 (队列2) 和诊断为普通感冒的对照组 (队列3).
- 参与者年龄≥60岁,没有先前的AD诊断,在2.75年的时间内观察到.
主要成果:
- 新的AD病例的累积发病率在暴露于NRTI的队列 (队列1) 中最低,在对照组 (队列3) 中最高.
- 根据年龄和性别调整的危险比率表明,与第2群组 (HR 0.88,p < 0.05) 和第3群组 (HR 0.84,p < 0.05) 相比,第1群组的AD风险显著降低.
- 一项亚组分析显示,NRTI暴露但没有蛋白酶抑制剂 (PI) 暴露的患者的AD风险降低.
结论:
- 接触NRTI与显著降低患阿尔茨海默病的风险有关.
- 这些发现支持研究RT抑制剂作为AD的潜在治疗途径.
- 进一步的前性临床试验和开发针对大脑RT的下一代药物是有必要的.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.人类免疫缺陷病毒人类免疫缺陷病毒核酸逆转录酶抑制剂 核酸逆转录酶抑制剂蛋白酶抑制剂是一种蛋白酶抑制剂.反向转录酶的使用反转录酶抑制剂的逆转录酶抑制剂身体基因重组组合体基因重组更多相关视频
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
992
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
826
相关概念视频
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:10Retrovirus Life Cycles
45.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.9K
02:30siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K